Clinical Trial Overview

Amgen (AMGN) announced on December 8, 2025, the initiation of a Phase 1/2 clinical trial (NCT07134088) to evaluate the safety and efficacy of subcutaneous (SC) blinatumomab in pediatric patients aged 12 years and younger with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL) who are minimal residual disease (MRD) positive. Blinatumomab is an Amgen BiTE (Bispecific T-cell Engager) platform-based drug that simultaneously targets CD19 (a B-cell surface antigen) and CD3 (a T-cell receptor), inducing T cells to directly destroy leukemia cells. Blincyto, the brand name for blinatumomab, received its first FDA approval in 2014 for adult Ph-negative R/R ALL, and the indication was expanded to pediatric R/R B-cell precursor ALL in 2018. In 2025, annual Blincyto sales reached USD 1.6 billion, making it a key growth driver for Amgen.

Strategic Significance of SC Formulation Transition

The currently approved blinatumomab has a short half-life of approximately 2 hours, requiring continuous intravenous (IV) infusion for 28 days. This necessitates hospitalization or the use of a portable pump (CADD-Legacy Pump) for pediatric patients, which structurally increases the burden on caregivers and healthcare costs, and directly affects treatment completion rates and quality of life (QoL). If the SC formulation is successful, it will enable outpatient administration, and, as seen with J&J's amivantamab/hyaluronidase SC transition, Amgen can defend its market share by upgrading the convenience of the same drug. For Amgen, this is also a life cycle management (LCM) strategy to extend the competitiveness of the Blincyto franchise after patent expiration.

Competitive Treatment Landscape

The key competitors in the pediatric R/R B-cell precursor ALL treatment market are Novartis' Kymriah (tisagenlecleucel, CD19 CAR-T, FDA approved in 2017, indication for patients under 25 years of age) and Pfizer's Besponsa (inotuzumab ozogamicin, CD22 antibody-drug conjugate, FDA approved in March 2024 with an additional indication for pediatric patients). Standard salvage chemotherapy (high-dose methotrexate, clofarabine-based combination therapy) has high toxicity and low response rates, leaving a significant unmet medical need. If SC blinatumomab is approved, it will be able to maintain a manufacturing and logistics cost advantage over CAR-T or ADC (antibody-drug conjugates) while securing a key differentiator: outpatient administration.

Clinical Design and Endpoints

Phase 1 will use a dose escalation design for the SC blinatumomab to establish the maximum tolerated dose (MTD) and safety profile. Phase 2 will set MRD-negative conversion rate and overall response rate (ORR) as the primary endpoints to quantify efficacy. The Phase 1/2 continuous combination design is a strategy to quickly transition to the efficacy cohort after early safety data is obtained, shortening the development timeline. It also opens the possibility of obtaining FDA Pediatric Rare Disease Priority Review designation.

Market Impact

The global ALL treatment market is approximately USD 3.7 billion in 2025, with pediatric patients accounting for approximately 68% of the total. If the SC transition is successful, it is expected that Blincyto sales will continue to grow, with both expansion into a new segment (pediatric outpatients) and conversion of existing IV prescriptions. Furthermore, as the first SC formulation transition for the BiTE platform, it can provide a blueprint for Amgen's other BiTE-based drugs (Imdelltra, tarlatamab, etc.) for formulation improvement strategies.